What is HUMATE-P?
HUMATE-P falls into a category of VWD treatments that are called von Willebrand factor/factor VIII (VWF/FVIII) replacement therapies.
These replacement therapies provide concentrated von Willebrand factor (VWF) to supplement or replace the VWF that is missing from your body.
By restoring VWF, replacement therapies such as HUMATE-P may help stop excessive bleeding, which may help you return to your everyday life.
HUMATE-P is the #1 prescribed VWF/FVIII concentrate treatment.*
- Extensive clinical experience
- Long record of success
HUMATE-P has been studied for more than 30 years and is preferred by more physicians and patients. In fact, it is the most prescribed von Willebrand factor/factor FVIII (VWF/FVIII) replacement therapy indicated for von Willebrand disease (VWD) in:
HUMATE-P provides reliable hemostatic control for all VWD types.
HUMATE-P is also proven effective across multiple types of bleeds, including:
- Spontaneous bleeding episodes (bleeding that occurs without an obvious cause) or after an injury, such as nosebleeds
- Trauma-induced bleeding episodes (bleeding caused by accidents or injuries)
- Bleeding occurring before and after surgery
CSL Behring's Integrated Safety System helps the product meet high quality and safety standards, thus reducing the risk of virus transmissions. The risk of virus transmission cannot be completely eliminated.
CSL Behring is dedicated to meeting the most stringent international standards for plasma-product safety in accordance with guidelines from worldwide regulatory agencies.
*Von Willebrand Factor Replacement Market Assessment. Third-Party Market Research.